Hot Investor Mandate 2: Cross-Border Fund Seeks Early Stage Therapeutics, Medtech, and Personalized Medicine in Chronic Diseases

7 Jul

An NJ-based venture investment firm focused on bridging Eastern and Western innovations and investment opportunities invests in early to mid-stage biopharma and medtech projects. With its own R&D facilities in China, in-licensing assets from the U.S. and Europe to China would be a consideration for their investment opportunities. With additional strategic investing partners in China, the size of investment can vary depending on the deal. The firm is currently looking for new opportunities globally.

The firm is interested in preclinical to phase 1/2 stage assets in biotech and medtech. The firm is open to all therapeutic modalities. Within medtech, the firm is more interested in personalized medicine/companion diagnostics and novel devices. In terms of disease areas, the firm is most interested in chronic diseases, liver and gastrointestinal conditions, but the firm generally avoids behavioral illnesses.

The firm is seeking strong management teams with products that could address large unmet medical need. The firm has R&D facilities in China that can facilitate product development and registration both for China local and global market. The firm is open to negotiate regional rights with flexible terms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: